New mRNA Melanoma Vaccine Trial Shows Promise
A patient reports six years of activity after participating in a trial combining an mRNA vaccine with immunotherapy.
Updated on Oct. 15, 2026 in Cancer
Gary Keblish, who was diagnosed with high-risk melanoma in 2019, recently shared his experience participating in a clinical trial for a combination mRNA cancer vaccine and immunotherapy. The trial tested the effectiveness of an experimental vaccine developed by Merck and Moderna.
Why it matters
This clinical trial represents a modern attempt to personalize cancer treatment by combining mRNA technology with immunotherapy. For patients with high-risk diagnoses, these research efforts are critical as scientists seek to improve long-term survival outcomes.
In a clinical trial setting, participants received a combined regimen of the immunotherapy drug Keytruda and an experimental mRNA cancer vaccine. While the patient remains active six years post-tumor removal, the trial's broad success metrics remain under further investigation.
The players
Gary Keblish
A schoolteacher and clinical trial participant who was treated for high-risk melanoma.
Jeffrey Weber
The deputy director of the Perlmutter Cancer Center at NYU Langone who specializes in melanoma research.
Merck
A global pharmaceutical company that develops oncology treatments, including Keytruda.
Moderna
A biotechnology company focused on mRNA-based vaccine development and therapeutic platforms.
The details
The treatment regimen involves a dual-action approach using Keytruda, an immunotherapy drug designed to help the immune system identify and attack cancer cells. This is paired with an experimental mRNA vaccine, which is engineered to prompt the body to recognize unique markers on a patient's tumor. During the process, the patient experienced neuropathy, a recognized potential side effect of the treatment protocol.
Timeline
2019: Gary Keblish received a high-risk melanoma diagnosis.
August 2026: Merck and Moderna announced clinical trial results.
October 15, 2026: Gary Keblish presented his experience at the STAT Summit in Boston.
Health Landscape
The development of mRNA cancer vaccines marks a transition toward highly personalized, immune-based oncology treatments. This approach builds upon the existing standard of care, such as immunotherapy, by potentially training the immune system to more precisely target malignant cells.
Patients diagnosed with high-risk melanoma should consult their oncologists about current clinical trial opportunities or new drug combinations. Managing side effects like neuropathy remains a key component of navigating long-term immunotherapy treatments.
The takeaway
Advancements in mRNA technology may offer new pathways for treating high-risk cancers like melanoma. Patients interested in emerging treatment options should maintain an open dialogue with their physician regarding active clinical trials.
Further reading
For more on the current state of oncology research, visit our Cancer section.
